교육

The Global Polycythemia Vera (PV) Treatment Market is witnessing steady growth, driven by increasing awareness, rising prevalence of the disease, and advancements in targeted therapies. Polycythemia Vera, a rare blood disorder characterized by the overproduction of red blood cells, poses significant health risks including blood clots, stroke, and heart complications.

The market is dominated by therapies aimed at controlling hematocrit levels, reducing the risk of thrombotic events, and managing symptoms. Standard treatments include phlebotomy, cytoreductive therapy, and targeted drugs such as JAK inhibitors. The introduction of innovative therapies and personalized medicine approaches has significantly enhanced patient outcomes.